We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon
Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
This undiscovered and heavily underpriced swedish company is one of only 3 companies who have a Biosmiliar of multiple blockbuster drug Lucentis and are close to NDA/MAA submission . And this company Xbrane is by far the cheapest in this area . Phase 3 readout expected for Q2 2020 and Xlucane thats the name of the Lucentis Biosimilar is already partnered with Stada . This low float stock is massive undervalued who targeting a almost $4 BILLION market .GL
Xbrane Biopharma (XBRANE .ST)
Market Cap: SEK 477,8 M ( = $49 M) Cash: $20 M Price: 31 SEK
Xbrane -Biosimilar Developer With Patented High Yield Technology
Lead Product Xlucane In Phase III With Commercial Partner STADA. Annual Sales Target Of €350 M. Income Of €100 M For Xbrane After COGS, SG&A And Partner Profit Sharing.
Addressing Attractive Biosimilar Market Opportunity. The Fastest Growing Segment Within Pharma Combined With Low Technical Risk
Patented Innovative High-yield Technology Platform Resulting In Low Production Costs
Strong Product Pipeline Targeting +€ 11 B In Originator Sales. Only Public Biosimilar Developments To Opdivo®And Cimzia®
Xbrane and STADA enter into a co-development agreement for Xlucane xbrane.com
Xbrane Biopharma AB ("Xbrane") and STADA Arzneimittel AG ("STADA") have entered into a co-development agreement for Xlucane, a Lucentis® (ranibizumab) biosimilar.
Strategic Biosimilar Development Partnership: STADA and Xbrane strengthen collaboration stada.com
Upcoming Milestones:
Q3 2019: 50% completion, i.e. close to 300 patients, of the patient recruitment into the ongoing phase 3trial “XPLORE” comparing biosimilar Xlucane with branded Lucentis
Q4 2019: last patient recruited into the “XPLORE”trial. The trial is designed to include approximately 580 participants in a randomised 1:1ratio to receive either Lucentisor investigational Xlucane
Q2 2020: initial head-line data covering the primary endpointfrom the”XPLORE”trial. The primary endpoint isthe change in best corrected visual acuity (BCVA)at week 8 compared to baseline using the ETDRS (Early TreatmentDiabetic Retinopathy Study, the worldwide standard for visual acuity testing) protocol
Q4 2020:initial submission for approval of Xlucane in Europe and the US
Q1 2021:final data covering secondary endpoints from the “XPLORE” study including 52-week efficacyand safety data
